# Schedules of Controlled Substances: Placement of Lemborexant in Schedule IV
> **Rule** · Final rule. · Published 2021-03-03 · 86 FR 12257
## Document
- **Document number:** 2021-04183
- **Category:** scheduling
- **Type:** Rule
- **Action:** Final rule.
- **Citation:** 86 FR 12257
- **Publication date:** 2021-03-03
## Abstract

This final rule adopts, without change, an interim final rule with request for comments published in the Federal Register on April 7, 2020, placing lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5- yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane- 1-carboxamide), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule IV of the Controlled Substances Act (CSA). With the issuance of this final rule, the Drug Enforcement Administration maintains lemborexant, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule IV of the CSA.

## Source
- [Federal Register document](https://www.federalregister.gov/documents/2021/03/03/2021-04183/schedules-of-controlled-substances-placement-of-lemborexant-in-schedule-iv)
---
*AI Analytics · CC0 1.0*